Elsevier

The Lancet

Volume 345, Issue 8945, 4 February 1995, Page 321
The Lancet

Letters to the Editor
Myocardial infarction, Arg 506 to Gin factor V mutation, and activated protein C resistance

https://doi.org/10.1016/S0140-6736(95)90310-0Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (124)

  • The association between Factor V Leiden with the presence and severity of coronary artery disease

    2014, Clinical Biochemistry
    Citation Excerpt :

    However, FVL's relation to CAD remains controversial. Several studies have failed to show a link between the presence of FVL and CAD [3,20–28]. In a large cohort study on 14,916 apparently healthy men the presence of the mutation was not found to be associated with an increased risk of myocardial infarction or stroke [3].

  • Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: Investigation of 507 patients with myocardial infarction

    2004, American Heart Journal
    Citation Excerpt :

    Our finding that there is a significant increased prevalence of factor V Leiden with resistance against activated protein C in a group of patients with confirmed myocardial infarction can be compared directly with other large studies individually. The biggest retrospective study,9 the multinational Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) study, which included 643 patients and 726 controls, did not demonstrate an increased prevalence of heterozygous factor V Leiden in patients with myocardial infarction (OR = 1.1363). Subgroups were investigated in each city where the study was performed.

View all citing articles on Scopus
View full text